Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $52.2 million.

  • Orchestra BioMed Holdings' Shares Outstanding (Diluted Average) rose 3871.46% to $52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.2 million, marking a year-over-year increase of 3871.46%. This contributed to the annual value of $36.8 million for FY2024, which is 1082.25% up from last year.
  • Latest data reveals that Orchestra BioMed Holdings reported Shares Outstanding (Diluted Average) of $52.2 million as of Q3 2025, which was up 3871.46% from $38.4 million recorded in Q2 2025.
  • Orchestra BioMed Holdings' 5-year Shares Outstanding (Diluted Average) high stood at $52.2 million for Q3 2025, and its period low was $9.2 million during Q1 2022.
  • Its 4-year average for Shares Outstanding (Diluted Average) is $31.2 million, with a median of $35.2 million in 2023.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first soared by 19965.72% in 2023, then surged by 342.87% in 2024.
  • Orchestra BioMed Holdings' Shares Outstanding (Diluted Average) (Quarter) stood at $15.0 million in 2022, then skyrocketed by 121.67% to $33.2 million in 2023, then rose by 10.82% to $36.8 million in 2024, then skyrocketed by 41.73% to $52.2 million in 2025.
  • Its last three reported values are $52.2 million in Q3 2025, $38.4 million for Q2 2025, and $38.2 million during Q1 2025.